|
|
News Breaks | | | | March 14, 2013 | | 12:14 EDT |  | ZIOP | Ziopharm confirms PFS is endpoint in palifosfamide trial, Feuerstein says
Ziopharm confirmed that progression-free survival, or PFS, is now an acceptable endpoint for approval in palifosfamide's Phase III trial, The Street's Adam Feuerstein said via Twitter, citing a company spokesperson. Shares of Ziopharm are up 5% to $5.53 in early afternoon trading. | |
|
News For ZIOP From The Last 14 Days Check below for free stories on ZIOP the last two weeks. |
|
|
| There are no results for ZIOP |
|
|
|
|
|
|
